Back to search

Article

Ablation of hepatocyte derived-FGL1 does not aggravate metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma

2024-12-23

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) begins with simple steatosis, which can progress to hepatocellular carcinoma (HCC). The pathogenesis of MASLD alters the secretion of hepatokines such as fibrinogen-like 1 (FGL1), a candidate mediator of liver steatosis and hyperglycemia. To investigate the contribution of FGL1 to liver diseases, we compared wild-type mice to mice with hepatocyte-spe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a047aeaf-3b88-58b4-9de7-40f9d8707370
DOI
10.1101/2024.12.23.628701
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ablation of hepatocyte derived-FGL1 does not aggravate metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinomaDOI 10.1101/2024.12.23.628701
Select a neighboring publication to make it the new centre.